Biological E to submit final data on its COVID-19 vaccine Corbevax till November end: Sources

By ANI | Published: October 14, 2021 08:09 PM2021-10-14T20:09:17+5:302021-10-14T20:20:02+5:30

Biological E will submit final data on COVID-19 vaccine Corbevax till November end, informed Government sources on Thursday.

Biological E to submit final data on its COVID-19 vaccine Corbevax till November end: Sources | Biological E to submit final data on its COVID-19 vaccine Corbevax till November end: Sources

Biological E to submit final data on its COVID-19 vaccine Corbevax till November end: Sources

Next

Biological E will submit final data on COVID-19 vaccine Corbevax till November end, informed Government sources on Thursday.

Earlier, on September 2, NITI Aayog Member (Health) VK Paul had said that the Hyderabad-based pharmaceutical company, Biological E, is expected to launch its vaccine against coronavirus in October this year.

Paul had toldthat Phase 3 of Biological E's trial is underway. "Stockpile is being produced. We should wait for the results. We hope it'll be in the next month or two. They've made a broad commitment that they'll supply a significant amount by year-end."

The Union Health Ministry had announced in June that the Biological E would supply 30 crore doses of Corbevax to India by December.

The Drug Controller General of India (DCGI) on Wednesday granted the company permission to conduct phase 2/3 clinical trials of the 'Made in India' COVID-19 vaccine for children of age group 5-18 years on certain conditions, sources told ANI.

Further, they said that the trial will be conducted across 10 sites in the county. "The permission has been given to Biological E after the recommendation from the Subject Expert Committee," they added.

It is to be noted that the government has made an advance payment of Rs 1,500 crore to Biological E for 30 crore vaccines.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in app